PLoS Med. 2011 Jan 25;8(1):e1000402. doi: 10.1371/journal.pmed.1000402.
Antimalarial drugs will be essential tools at all stages of malaria elimination along the path towards eradication, including the early control or "attack" phase to drive down transmission and the later stages of maintaining interruption of transmission, preventing reintroduction of malaria, and eliminating the last residual foci of infection. Drugs will continue to be used to treat acute malaria illness and prevent complications in vulnerable groups, but better drugs are needed for elimination-specific indications such as mass treatment, curing asymptomatic infections, curing relapsing liver stages, and preventing transmission. The ideal malaria eradication drug is a coformulated drug combination suitable for mass administration that can be administered in a single encounter at infrequent intervals and that results in radical cure of all life cycle stages of all five malaria species infecting humans. Short of this optimal goal, highly desirable drugs might have limitations such as targeting only one or two parasite species, the priorities being Plasmodium falciparum and Plasmodium vivax. The malaria research agenda for eradication should include research aimed at developing such drugs and research to develop situation-specific strategies for using both current and future drugs to interrupt malaria transmission.
抗疟药物将是消除疟疾过程中各个阶段的重要工具，包括早期控制或“攻击”阶段以降低传播率，以及后期维持传播中断、防止疟疾再次输入和消除最后剩余的感染焦点。药物将继续用于治疗急性疟疾疾病和预防脆弱人群的并发症，但需要更好的药物来满足消除疟疾的具体适应症，如大规模治疗、治愈无症状感染、治愈复发的肝脏阶段和预防传播。理想的消除疟疾药物是一种适合大规模使用的联合配方药物，可以在一次就诊时以不频繁的间隔给予，并且可以根治所有感染人类的五种疟原虫的所有生命周期阶段。在实现这一最佳目标之前，非常理想的药物可能有一些局限性，例如只针对一种或两种寄生虫物种，优先考虑恶性疟原虫和间日疟原虫。消除疟疾的研究议程应包括开发此类药物的研究，以及开发针对当前和未来药物的具体情况策略的研究，以中断疟疾传播。
